Scientech Research LLC Raises Position in Twist Bioscience Co. (NASDAQ:TWST)

Scientech Research LLC raised its stake in Twist Bioscience Co. (NASDAQ:TWST) by 102.7% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 31,435 shares of the company’s stock after buying an additional 15,924 shares during the quarter. Scientech Research LLC’s holdings in Twist Bioscience were worth $1,549,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. EdgeRock Capital LLC purchased a new stake in shares of Twist Bioscience in the second quarter worth approximately $43,000. Blue Trust Inc. raised its stake in shares of Twist Bioscience by 2,912.8% in the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after purchasing an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new stake in shares of Twist Bioscience in the second quarter worth approximately $61,000. Nisa Investment Advisors LLC raised its stake in shares of Twist Bioscience by 31.3% in the second quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after purchasing an additional 546 shares during the last quarter. Finally, CWM LLC raised its stake in shares of Twist Bioscience by 27.4% in the second quarter. CWM LLC now owns 2,437 shares of the company’s stock worth $120,000 after purchasing an additional 524 shares during the last quarter.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. JPMorgan Chase & Co. increased their price objective on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research note on Monday, August 5th. Barclays decreased their price target on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating for the company in a research report on Monday, August 5th. Robert W. Baird increased their price target on Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a research report on Monday, August 5th. Guggenheim assumed coverage on Twist Bioscience in a research report on Tuesday, June 4th. They set a “buy” rating and a $53.00 price target for the company. Finally, TD Cowen increased their price target on Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. One research analyst has rated the stock with a sell rating and eight have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $48.22.

Insider Transactions at Twist Bioscience

In other news, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the transaction, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at $23,259,849.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, SVP Paula Green sold 1,137 shares of the firm’s stock in a transaction on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the completion of the transaction, the senior vice president now directly owns 88,837 shares of the company’s stock, valued at $3,547,261.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Emily M. Leproust sold 1,730 shares of the firm’s stock in a transaction on Friday, September 20th. The stock was sold at an average price of $46.94, for a total value of $81,206.20. Following the completion of the transaction, the chief executive officer now directly owns 495,523 shares of the company’s stock, valued at $23,259,849.62. The disclosure for this sale can be found here. Insiders sold 17,386 shares of company stock valued at $770,915 over the last three months. Company insiders own 3.92% of the company’s stock.

Twist Bioscience Price Performance

NASDAQ:TWST opened at $47.08 on Friday. The business has a fifty day simple moving average of $46.46 and a two-hundred day simple moving average of $43.24. Twist Bioscience Co. has a 1 year low of $14.42 and a 1 year high of $60.90. The company has a market capitalization of $2.76 billion, a P/E ratio of -14.01 and a beta of 1.76.

Twist Bioscience (NASDAQ:TWST) last released its earnings results on Friday, August 2nd. The company reported ($1.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). Twist Bioscience had a negative return on equity of 32.17% and a negative net margin of 74.63%. The firm had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. During the same period in the prior year, the business earned ($1.01) earnings per share. The business’s quarterly revenue was up 27.7% compared to the same quarter last year. As a group, analysts anticipate that Twist Bioscience Co. will post -3.13 earnings per share for the current year.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.